

January 30, 2020

Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum

Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that Dr. Brian Murphy, Chief Executive Officer, Emerald Bioscience will present at the upcoming 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Conference.

9th Annual Glaucoma 360 New Horizons Forum

Dr. Brian Murphy will present an overview of Emerald Bioscience's cannabinoid pipeline for ocular diseases, including its lead candidate NB1111 for the management of glaucoma, at the 9th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 7, 2020 at the Grand Hyatt Union Square in San Francisco, CA. This meeting, held by the Glaucoma Research Foundation, brings together key clinical and industry leaders in a unique exchange on research innovation and advances in glaucoma treatment.

Details of the presentation are as follows:

- Session: New Horizons in Pharmaceuticals
- Date and Time: Friday, February 7, 2020 at 2:25-3:05 PM PT
- Location: Grand Hyatt Union Square, Grand Ballroom, San Francisco, CA

The 2020 meeting will feature more than 60 speakers from companies developing innovative glaucoma therapies and diagnostics. This full-day meeting co-founded and co-chaired by **Adrienne L. Graves, PhD** and **Andrew G. Iwach, MD**, spotlights new and promising developments to diagnose and treat glaucoma, a leading cause of preventable blindness worldwide. Since its inception in 2012, this meeting has grown substantially, attracting key clinical, scientific, industry, financial, and regulatory leaders from across the United States and around the world.

BIO CEO & Investor Conference

Dr. Murphy will present a corporate overview at the BIO CEO & Investor Conference to be held on February 10-11, 2020 at the Marriott Marquis in New York, NY with follow-up investor meetings held throughout the conference.

Details of the presentation are as follows:

- Date and Time: Tuesday, February 11, 2020 at 2:15 PM ET
- Location: Marriott Marquis, Brecht Room, New York, NY

About Emerald Bioscience, Inc.

Emerald Bioscience is a biopharmaceutical company headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Emerald is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Emerald's strategy is to clinically develop a number of proprietary biosynthetic compounds, alone or in combination with corporate partners.

For more information, visit www.emeraldbio.life

CONTACT

Douglas Cesario

Chief Financial Officer

Email: doug@emeraldbio.life

Phone: 949-336-3437

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, product branding, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "contemplates," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.



Source: Emerald Bioscience, Inc.